کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2195925 | 1550884 | 2014 | 4 صفحه PDF | دانلود رایگان |
• Aging is a multi-factorial process.
• A reduction in these age-related diseases will enhance the quality of life.
• Endocrine therapy, especially hormone-replacement therapy has important limitations.
• Critical genes within endocrine regulatory networks represent anti-aging targets.
Aging represents an important health issue not only for the individual, but also for society in general. Burdens associated with aging are expanding as longevity increases. This has led to an enhanced focus on issues related to aging and age-related diseases. Until recently, anti-aging endocrine-therapy has been largely limited to hormone-replacement therapy (HRT) that is associated with multiple side effects, including an increased risk of cancer. This has greatly limited the application of HRT in anti-aging therapy. Recently, the focus of anti-aging research has expanded from endocrine signaling pathways to effects on regulatory gene networks. In this regard, the GHRH-GH-IGF-1/Insulin, TOR-S6K1,NAD+-Sirtuin, P53, Klotho and APOE pathways have been linked to processes associated with age-related diseases, including cancer, cardiovascular disease, diabetes, osteoporosis, and neurodegenerative diseases, all of which directly influence health in aging, and represent key targets in anti-aging therapy.
Journal: Molecular and Cellular Endocrinology - Volume 394, Issues 1–2, 25 August 2014, Pages 115–118